Magle Chemoswed Holding AB (publ) (FRA:52X)

Market Cap	7.50M -87.4%
Revenue (ttm)	27.40M +43.6%
Net Income	-14.77M
EPS	-0.72
Shares Out	n/a
PE Ratio	n/a
Forward PE	2.78
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.6200
Previous Close	0.6300
Day's Range	0.6200 - 0.6300
52-Week Range	0.6200 - 2.4400
Beta	n/a
RSI	25.59
Earnings Date	May 15, 2026

About FRA:52X

Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease. The company also offers EmboCept S, a microsphere-based medical dev...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1944
• Employees: 144
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 52X

Financial Performance

In 2024, FRA:52X's revenue was 240.57 million, an increase of 40.27% compared to the previous year's 171.50 million. Earnings were 11.94 million, a decrease of -1.91%.

Financial numbers in SEK